[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-coronary-syndromes-acs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-coronary-syndromes-acs":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,46,75,104,134,161,188,222,247,276,304,331,353,373,412,444,479,500,541,571,600,625,654,686,718],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100640367","phase-1-the-pharmacokinetics-and-pharmacodynamics-study-of-evategrel-cg-0255-besylateand-plavix-in-healthy-participants-100640367",false,"NCT07619885","The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants","A Pivotal Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of CG-0255 Besylate and Plavix® in Healthy Participants","Inclusion Criteria:\n\n* Participants must be fully informed about the study, willing to participate, and sign the informed consent document prior to any procedure.\n* Healthy male and female participants, aged 18 to 55 years (inclusive) at time of signing informed consent form.\n* Body mass index (BMI) between 18 and 32 kg\u002Fm2 (inclusive) at screening and body weight between 45 and 120 kg (inclusive).\n* Smoking \\\u003C 10 cigarettes (10-20 mg of nicotine\u002Fmonth) or equivalent amount of nicotine products per month within 6 months prior to screening and agree to abstain from tobacco and\u002For nicotine products during the study.\n* Generally normal health, or abnormalities deemed non-clinically significant by the Investigator or designee based on medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory tests at the screening and at the admission.\n* For female participants,\n\n  1. Woman of child-bearing potential (WOCBP) must be non-pregnant and non-lactating, and must agree to use highly effective contraceptive methods and abstain from egg collection or donation from the screening period to 3 months after the last dose of the study treatment (CG-0255 Besylate or Plavix®). The male partner of a female participant also needs to use condoms during this period.\n  2. Woman of non-childbearing potential (WONCBP) must be post menopausal (spontaneous amenorrhea for at least 12 consecutive months prior to dosing) with confirmation by documented FSH levels ≥40 mIU\u002FmL; or surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or bilateral tubal ligation) at least 3 months prior to dosing.\n* Male participants considered fertile must agree to not plan to father a child, not donate sperm and take effective contraceptive methods from the screening period to 3 months after the last dose of the study treatment. The female partner of a male participant also needs to use a highly effective contraceptive method during this period.\n* Male participants (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the screening period to 3 months after the last dose of the study treatment.\n* Participants must be able to communicate well with the Investigator or designee, as well as understand and adhere to the study's requirements.\n\nExclusion Criteria:\n\n* Difficulty with venous blood collection or a history of fainting upon seeing blood or needles.\n* Clinically relevant drug intolerance or allergy or known or suspected hypersensitivity to any component of CG-0255 Besylate or Plavix®, or other related drugs.\n* Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days (or 5 times half-life, whichever is longer) prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days (or 5 times half-life, whichever is longer) prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.\n* Current or unresolved digestive tract diseases (dyspepsia, gastroesophageal reflux, gastro-hemorrhage, or digestive tract ulcer disease) within the past 6 months, or frequent (\\> 1 time\u002Fweek) digestive tract symptoms including dysphagia, abdominal pain, abdominal distension, acid regurgitation, belching, hematemesis, bloody stool, anorexia, nausea, heartburn, and other symptoms that may increase the risk of bleeding, as determined by the Investigator or designee.\n* Any clinically significant diseases including but not limited to pulmonary, cardiovascular, gastrointestinal, hematological, endocrinological, immunological, dermatological, malignant diseases, mental and nervous systems, and other related diseases or any other condition at the discretion of the Investigator or designee.\n* History of previous or current active bleeding (such as intracranial hemorrhage, gastrointestinal hemorrhage, urethral hemorrhage, hemoptysis, vitreous hemorrhage, bleeding caused by stool and hemorrhoids), transient ischemic attack or stroke, abnormal bleeding (such as prolonged bleeding time after tooth extraction), presence of petechiae and\u002For ecchymosis on physical examination, or suspected vascular malformations (such as aneurysms or early-onset stroke, not exceeding the age limit specified in the inclusion criteria).\n* Hemoglobin \\\u003C120 g\u002FL for males and \\\u003C110 g\u002FL for females at screening.\n* Medication history of NSAIDs (including Aspirin) or other drugs that may affect coagulation function (e.g, oral anticoagulants) within 4 weeks before the screening.\n* Platelet count \\\u003C 120 × 10\\^9\u002FL at screening.\n* Laboratory measures with values above the 1.5 × upper limits of normal (ULN) and deemed clinically significant by the Investigator or designee for the alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST).\n* Clinically significant ECG abnormalities (QTcF interval ≥ 450 ms for male, ≥ 470 ms for female (Fridericia's Correction)) or vital signs abnormalities (systolic BP lower than 90 or over 140 mmHg, diastolic BP lower than 50 or over 90mmHg, HR less than 50 or over 100 bpm, or RR less than 10 or over 22 bpm) at screening.\n* Major surgery within 3 months prior to the first dose of study treatment or plans for surgery during the study.\n* Use of prescription, nonprescription or dietary supplements (e.g. food supplements and herbal supplements) within 14 days or 5 times the half life (whichever is longer) prior to the first dose of study treatment (excluding drug products without significant systemic absorption at the discretion of the Investigator or designee), or depot injection or implant within 3 months prior to first dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily).\n* Vaccinated within 14 days prior to the first dose of study treatment or planned to be vaccinated during the study.\n* Consuming quinine containing products, including quinine water, tonic water bitter lemon, jello shots, any quinine preparations or Cinchona tree bark reparations (e.g., herbal medications containing Cinchona tree bark), and grapefruit or products containing grapefruit, or participants have engaged strenuous exercise or any other factors affecting drug absorption, distribution, metabolism and excretion within 7 days before the first dose of study treatment.\n* History of drug abuse within 1 year before screening, or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine \\[PCP\\], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.\n* Positive urine drug screen, urine cotinine test, or alcohol breath test at screening or at the admission.\n* Positive pregnancy test or lactating female participant at screening or at the admission.\n* Donation of plasma within 7 days prior to the first dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to the first dosing.\n* History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).\n* Known hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.\n* Excessive drinking of tea, coffee, or caffeine-containing beverage (\\>600 mg\u002Fday) within 30 days before screening; intake of caffeine- or xanthine rich foods or drinks (e.g., coffee, tea, chocolate, cola drinks) within 48 hours prior to the first dose of study treatment, which may metabolize into caffeine or xanthine.\n* Positive screening for human immunodeficiency virus (HIV) antigen and antibody, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) antibody at screening.\n* Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin as calculated per CKD-EPI equation, at screening.\n* Use of any drugs known to induce or inhibit hepatic drug metabolism (including CYP2C19 inducers or inhibitors) within 30 days prior to the first study drug administration or 5 half-lives (whichever is longer) until the end of the study.\n* Participants deemed ineligible to participate in this study by the Investigator or designee.",true,"ALL","18 Years","55 Years",{"count":22,"type":23},136,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes. This is a randomized, open-label and Plavix®-controlled study to compare the PK and PD of CG-0255 Besylate and Plavix® in healthy participants.",[29,30,31,32],"Acute Coronary Syndromes (ACS)","Recent Myocardial Infarction","Recent Stroke","Peripheral Arterial Disease","RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":23},"2026-06",{"date":41,"type":23},"2026-12",{"name":43,"class":44},"Shanghai CureGene Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100642567","effects-of-icosapent-ethyl-on-coronary-plaque-inflammation-and-ventricular-remodeling-100642567","NCT07641257","Effects of Icosapent Ethyl on Coronary Plaque, Inflammation, and Ventricular Remodeling","Impact of Icosapent Ethyl on Ventricular Remodeling, Inflammation, and Coronary Plaque Stability in Patients With Acute or Chronic Coronary Syndrome: A Prospective, Observational, Real-World Study","Inclusion Criteria:\n\n* Age 18 years and older, of any sex.\n\n  * Definite diagnosis of chronic coronary syndrome (CCS) according to the Chinese Guidelines for the Diagnosis and Management of Patients with Chronic Coronary Syndrome, or acute coronary syndrome (ACS) according to the 2025 ACC\u002FAHA\u002FACEP\u002FNAEMSP\u002FSACI Guideline for the Management of Acute Coronary Syndromes.\n  * Laboratory evaluation showing fasting triglycerides (TG) \\>= 1.7 mmol\u002FL.\n  * Ability to fully understand the study purpose, voluntary participation, and provision of signed written informed consent.\n\nExclusion Criteria:\n\n* Women who are planning a pregnancy, currently pregnant, or lactating.\n\n  * Known hypersensitivity or allergic reaction to the active ingredient of icosapent ethyl (IPE) or any of its excipients (applicable to patients in the exposure cohort).\n  * Diagnosed with major life-threatening conditions such as malignant tumors, end-stage lung disease, or advanced neurodegenerative diseases, with a life expectancy of less than 12 months.\n  * Concurrent participation in any other interventional clinical trial involving investigational drugs or medical devices.\n  * Any other condition or severe non-compliance that, in the judgment of the investigator, makes the patient unsuitable for enrollment in this study.",{"count":54,"type":23},420,"12 Months","OBSERVATIONAL","Even with standard treatments like statins, patients with coronary artery disease often face a residual risk of further heart events. This risk is largely driven by ongoing inflammation and unstable fatty plaques in the heart's blood vessels. Icosapent ethyl (IPE) is a highly purified prescription medication known to improve cardiovascular outcomes, but its detailed effects on the heart's structure and inflammation in everyday clinical practice need further exploration.\n\nThis study is a prospective, observational, real-world study designed to evaluate the effectiveness of IPE in patients with Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS). The study plans to enroll 420 patients who will be followed for 12 months. Based on their routine clinical prescriptions, participants will be grouped into a control group (receiving standard cardiovascular care, including statins) and an exposure group (receiving standard care plus IPE).\n\nThroughout the 1-year follow-up, researchers will conduct regular blood tests and advanced heart imaging. The main goal is to determine if adding IPE to standard therapy leads to a more significant reduction in inflammation. Additionally, the study will observe how IPE affects the stability of coronary plaques and the healing process of ventricular remodeling in a real-world clinical setting.",[29,59,60,61,62,63],"Chronic Coronary Syndrome","Coronary Artery Disease","Atherosclerosis Cardiovascular Disease","Ventricular Remodeling","Inflammation","NOT_YET_RECRUITING","2026-06-08",{"date":67,"type":37},"2026-06-11",{"date":69,"type":23},"2026-05-30",{"date":71,"type":23},"2029-05-30",{"name":73,"class":74},"Ruijin Hospital","OTHER",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":45},"100639617","the-core---fr-clinical-trial-100639617","NCT07598565","The CORE - μFR Clinical Trial","μFR -Guided Complete Revascularization in Patients With Acute Coronary Syndromes","Inclusion Criteria:\n\n1. Patients presenting with ACS within 72 hours of successful culprit PCI\n2. Residual coronary artery disease, defined as at least one additional stenosis in any non-culprit vessel (NCV) with the following characteristics:\n\n   1. at least 50% diameter stenosis by visual assessment\n   2. a vessel diameter of at least 2.5 mm\n   3. amenable to successful PCI\n\nExclusion Criteria:\n\n1. Cardiogenic shock or severe heart failure (NYHA class ≥III)\n2. Severely impaired renal function: creatinine \\>2 mg\u002Fdl or estimated glomerular filtration rate (eGFR) \\\u003C30 ml\u002Fmin\u002F1,73 m²\n3. Allergy to iodine-containing contrast agents which cannot be adequately pre-medicated\n4. Pregnancy or intention to become pregnant during the trial\n5. Life expectancy less than one year\n6. Ambiguity in the identification of the culprit vessel\u002Flesion\n7. Clinical presentation as myocardial infarction and non-obstructive coronary artery disease (MINOCA) and\u002For Tako-Tsubo Syndrome\n8. Any ambiguity in the diagnosis of ACS\n9. Inability to provide informed consent\n10. Patients with only one coronary artery lesion with diameter stenosis \\>90% and\u002For TIMI flow \\\u003C3\n11. Patients in whom the NCV is treated at the time of the index procedure\n12. An interrogated lesion is at the site of a myocardial bridge\n13. An interrogated lesion is a culprit lesion responsible for the acute myocardial infarction\n14. An interrogated lesion is in a bypass graft\n15. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification\n16. Severe vessel overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to μFR measurement",{"count":83,"type":23},350,[85],"NA","Acute coronary syndromes (ACS) are frequently associated with multivessel coronary artery disease (CAD), and current guidelines recommend complete revascularization beyond the culprit lesion. Angiography-guided PCI is the standard approach, but anatomical assessment does not always reflect the functional significance of intermediate lesions, while FFR-guided strategies are limited by the need for pressure wires and hyperemia. Murray-law-based quantitative flow ratio (μFR) is a wire-free angiography-derived physiological index that may improve decision-making for revascularization in ACS patients.\n\nThe Core-μFR is an investigator-driven, multicenter, randomized, open-label and prospective trial designed to evaluate whether μFR can act as a gatekeeper for complete revascularization in patients with ACS and multivessel disease by identifying non-culprit lesions that truly require PCI.\n\nPatients with ACS (either STEMI or NSTE-ACS) undergoing primary PCI will be considered eligible if they present multivessel CAD on visual assessment with the intention to treat the non-culprit vessel in a staged procedure within the same hospitalization. After the pPCI, eligible patients will be randomized to either group A or group B and μFR will be performed in a blinded fashion with the operator unaware of the functional result. Patients in group A will undergo a staged PCI of all NCVs guided by coronary angiography, as per standard of care. In group B, μFR will be used as a gatekeeper for staged revascularization. Operators will only be informed whether at least one non-culprit vessel is μFR-positive, without disclosure of the specific vessel involved or the μFR values. If at least one non-culprit vessel has μFR ≤0.80, patients will undergo angiography-guided PCI of all non-culprit vessels previously deemed suitable for treatment by visual assessment. If μFR is \\>0.80 in all non-culprit vessels, staged PCI will be deferred and the patient will be discharged without further revascularization. Finally, to test the functional reproducibility, a blinded post-hoc μFR assessment will be performed on the baseline angiograms of the staged procedures in all the patients undergoing complete revascularization. Clinical follow-up will be performed at 30 days and 1 year from randomization.",[29,88,89,90],"NSTEMI - Non-ST-Segment Elevation Myocardial Infarction","STEMI - ST Elevation Myocardial Infarction","Multivessel Coronary Artery Disease",[92,93,94],"Murray-law based Quantitative Flow Ratio (μFR)","Non culprit vessel","Revascularization","2026-05-19",{"date":97,"type":37},"2026-05-22",{"date":99,"type":23},"2026-05-18",{"date":101,"type":23},"2028-06-30",{"name":103,"class":74},"University of Roma La Sapienza",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":24,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":45},"100637232","phase-3-analysis-of-growth-differentiation-factor-15-gdf-15-mid-regional-proadrenomedullin-mr-proadm-and-persepsin-levels-in-patient-in-acute-coronary-syndrome-patients-with-pneumonia-with-or-without-influenza-vaccination-100637232","NCT07604103","Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination","Analysis of the Relationship Between Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patients With Acute Coronary Syndrome With Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) With Influenza Vaccination","Inclusion Criteria:\n\n* Adult male patients (\\\u003C 65 years old).\n* History of being an active smoker.\n* Confirmed diagnosis of Acute Coronary Syndrome (ACS) and Pneumonia based on clinical, laboratory, and radiological criteria.\n* Demonstrated clinical improvement (stabilization) after receiving standard ACS and Pneumonia therapy in the acute intrahospital phase.\n* Willing to undergo all study procedures and sign the Informed Consent form.\n\nExclusion Criteria:\n\n* Presence of absolute contraindications to pneumococcal and influenza vaccination (history of anaphylactic reactions to vaccine components).\n* Patients with malignancies (cancer), systemic autoimmune diseases, or those currently on long-term immunosuppressant therapy.\n* Patients with End-Stage Renal Disease (ESRD) or severe liver dysfunction that could confound inflammatory biomarker values.\n* Patients with persistently unstable hemodynamic conditions or unresolved cardiogenic shock during the acute care phase.\n* Patient death before the observation period (up to post-vaccination) is completed.\n* Patient unilaterally resigns or withdraws consent during the study.\n* Lost to follow-up during scheduled outpatient clinic visits or scheduled follow-up biomarker evaluations.","65 Years",{"count":113,"type":23},60,[115],"PHASE3","The goal of this observational study is to analyze the relationship between various biomarkers (GDF-15, MR proADM, and Presepsin) in patients with Acute Coronary Syndrome (ACS) who also have Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) and have received Influenza vaccinations.\n\nThe main questions it aims to answer are:\n\n* Is there a significant correlation between the levels of these specific biomarkers and the clinical outcomes or inflammatory status of these patients?\n* How does Influenza vaccinations relate to the levels of these biomarkers in the context of ACS with comorbid respiratory conditions? Researchers will compare the levels of these biomarkers across the participant group to see if they can serve as indicators of the patients' health status or the impact of the vaccinations.\n\nParticipants will:\n\n\\- Undergo clinical assessment for Acute Coronary Syndrome, Pneumonia, and COPD. Provide medical history regarding Influenza vaccination status. Provide blood samples for the measurement of GDF-15, MR proADM, and Presepsin levels.",[29,118,119],"Pneumonia","COPD (Chronic Obstructive Pulmonary Disease)",[121,122,123,124,118,125],"GDF-15","MR proADM","Persepsin","Acute coronary syndrome","influenza vaccination","2026-05-16",{"date":97,"type":37},{"date":129,"type":37},"2026-01-01",{"date":131,"type":23},"2026-10-10",{"name":133,"class":74},"University of Brawijaya",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":146,"conditions":147,"keywords":152,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100637529","computed-tomography-angiography-based-procedural-planning-in-percutaneous-coronary-intervention-100637529","NCT07592312","Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE: Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Ability to provide written informed consent\n* Patients undergoing coronary computed tomography angiography (CCTA) for suspected coronary artery disease or for diagnostic work-up of stabilized acute coronary syndrome\n* Presence of at least one target coronary lesion meeting one of the following CCTA criteria:\n\n  * Severe coronary diameter stenosis (70-99%) in one or more coronary arteries according to CAD-RADS 4A or 4B classification and at least one of the following:\n  * CT-derived fractional flow reserve (CT-FFR) ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n  * Left main coronary artery stenosis ≥50%\n  * Ostial or proximal left anterior descending artery, dominant left circumflex artery, or dominant right coronary artery stenosis ≥50% and at least one of the following:\n  * CT-FFR ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n* Planned clinically indicated invasive coronary angiography with operator decision to proceed with PCI\n\nExclusion Criteria:\n\n* Contraindication to iodinated contrast media, including severe allergy or contrast-induced nephropathy\n* Poor-quality or non-diagnostic CCTA imaging\n* Target lesions involving in-stent restenosis\n* Chronic total occlusion target lesions\n* Operator decision to treat a vessel not identified as a target vessel by the CCTA core laboratory analysis\n* Pregnancy or breastfeeding\n* Patients referred for coronary artery bypass graft surgery after invasive coronary angiography\n* Participation in another investigational drug or drug-coated device study\n* Inability to provide informed consent","80 Years",{"count":144,"type":23},200,[85],"The goal of this clinical trial is to learn whether coronary CT angiography (CCTA)-guided planning improves the efficiency and outcomes of percutaneous coronary intervention (PCI) in adults with coronary artery disease. It will also evaluate the feasibility and safety of using a CT-based \"virtual PCI plan\" during coronary interventions.\n\nThe main questions it aims to answer are:\n\n* Does CCTA-guided PCI reduce procedural time, radiation exposure, and contrast dye use compared with standard PCI?\n* Does CCTA-guided PCI improve procedural outcomes and stent optimization?\n* How often do operators follow or deviate from the CT-based procedural plan?\n* What medical problems or complications occur during and after CCTA-guided PCI?\n\nResearchers will compare CCTA-guided PCI with standard angiography-guided PCI to determine whether CT-derived procedural planning improves PCI efficiency and clinical outcomes.\n\nParticipants will:\n\n* Undergo PCI guided either by a CCTA-based virtual planning strategy or by standard clinical practice\n* Attend follow-up assessments at 1 month, 6 months, and 1 year\n* Undergo routine clinical evaluations and imaging assessments related to their PCI procedure\n* Be monitored for procedural complications, symptoms, repeat procedures, and cardiovascular outcomes during follow-up\n\nThe study will also include a parallel observational registry for patients whose coronary lesions are deferred from PCI, to evaluate their long-term clinical outcomes.",[148,59,29,149,150,151],"Coronary Arteries Disease","Myocardial Ischemia","Percutaneous Coronary Intervention","Coronary Computed Tomography Angiography",[60,153,150,151],"Chronic Coronary Disease","2026-05-13",{"date":99,"type":37},{"date":99,"type":23},{"date":158,"type":23},"2028-12-30",{"name":160,"class":74},"University of Galway",{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":45},"100630430","mpv-as-a-predictor-for-acs-in-patients-with-masld-100630430","NCT07487571","MPV as a Predictor for ACS in Patients With MASLD","Mean Platelet Volume as a Predictor for Acute Coronary Syndrome in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease","MPV\u002FACS MASLD","Inclusion Criteria:\n\n* Adult patients aged ≥18 years.\n* Confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) based on clinical, laboratory, and imaging criteria).\n* Patients diagnosed with acute coronary syndrome (unstable angina, NSTEMI, or STEMI) for Group I.\n* MASLD patients without clinical or electrocardiographic evidence of acute coronary syndrome for Group II.\n* Patients who provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with chronic liver diseases other than MASLD (e.g., viral hepatitis, autoimmune hepatitis, alcoholic liver disease).\n* Patients with known hematological disorders affecting platelet count or function.\n* Patients receiving antiplatelet or anticoagulant therapy prior to blood sampling.\n* Patients with active infection, inflammatory diseases, or malignancy.\n* Patients with chronic kidney disease or end-stage renal failure.\n* Pregnant or lactating females.",{"count":113,"type":23},"The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Sohag University Hospital.",[172,29],"Metabolic Dysfunction-Associated Steatotic Liver Disease",[174,175,176,177,178],"Mean platelet volume","Cardiovascular risk","Platelet activation","Metabolic syndrome","Liver staetosis","2026-04-30",{"date":181,"type":37},"2026-05-06",{"date":183,"type":23},"2026-05-05",{"date":185,"type":23},"2026-12-01",{"name":187,"class":74},"Sohag University",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100636308","prehospital-point-of-care-hs-troponin-i-for-rule-out-of-acute-myocardial-infarction-in-patients-without-st-segment-elevation-100636308","NCT07563998","Prehospital Point-of-Care Hs-Troponin I for Rule-Out of Acute Myocardial Infarction in Patients Without ST-Segment Elevation","Prehospital Point-of-Care High-Sensitivity Troponin I for Rule-Out of Acute Myocardial Infarction in Suspected Non-ST-Segment Elevation Acute Coronary Syndrome: A Pilot Study","Pre-POCT TnI","Inclusion Criteria:\n\n* Age 18 years or older\n* Assessed by one of the participating EMS units equipped for POCT sampling\n* Presentation with symptoms suggestive of acute coronary syndrome\n* Planned transport to hospital for further evaluation\n\nExclusion Criteria:\n\n* ST-segment elevation on prehospital electrocardiogram\n* Clinical condition requiring immediate life-saving intervention precluding study procedures\n* Interhospital transport\n* Prior inclusion in the study within 30 days",{"count":197,"type":23},500,"People who call emergency medical services (EMS) with chest pain or other possible heart-related symptoms are often taken to hospital for further testing. However, only a small proportion of these patients are ultimately diagnosed with a serious heart condition such as a heart attack. This means that many patients undergo hospital transport and evaluation even though their risk is low.\n\nIn hospitals, a blood test called high-sensitivity cardiac troponin is commonly used to help diagnose or rule out heart attacks. It is not yet well established whether this type of test can be used safely and effectively earlier, in the prehospital setting.\n\nThis study will investigate whether it is feasible to measure high-sensitivity troponin in the ambulance and how well the test can identify patients at low risk of serious heart conditions. A small blood sample will be taken as part of routine care and analyzed using a portable device. The test result will not be used to guide treatment or decisions during the study.\n\nThe study will assess how well the test predicts heart-related events within 30 days and how practical it is to perform the test in real-life emergency settings. The results may help guide future research on how to improve early assessment and decision-making for patients with suspected heart disease.",[200,29],"Myocardial Infarction (MI)",[202,203,204,205,206,207,208,209,210,211,212],"Prehospital","Emergency Medical Services","Point-of-Care Testing","POCT","High-Sensitivity Troponin I","Chest Pain","Non-ST Elevation","Diagnostic Accuracy","Risk Stratification","Major Adverse Cardiac Events","MACE","2026-04-26",{"date":215,"type":37},"2026-05-04",{"date":217,"type":23},"2026-05-15",{"date":219,"type":23},"2027-06-30",{"name":221,"class":74},"Central Denmark Region",{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":229,"targetDuration":231,"studyType":56,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":45},"100632601","qatar-cardiometabolic-retrospective-cohort-analysis-using-artificial-intelligence-100632601","NCT07515807","Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence","QCRC-AI","Inclusion Criteria:\n\n* Age ≥ 18\n* Qatari and Arab participants\n* Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)\n* Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%\n\nExclusion Criteria:\n\n* Non-Qatari or non-Arab participants\n* Non-diabetic: HbA1C \\\u003C 5.7%\n* This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.",{"count":230,"type":23},10000,"2 Years","Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.",[234,29,235,236,237],"Cardio Vascular Disease","Type 2 Diabetes","Pre Diabetes","Artifical Intelligence","2026-04-15",{"date":240,"type":37},"2026-04-21",{"date":242,"type":23},"2026-07-16",{"date":244,"type":23},"2030-07-16",{"name":246,"class":74},"Weill Cornell Medical College in Qatar",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":255,"targetDuration":4,"studyType":24,"phases":257,"briefSummary":259,"conditions":260,"keywords":263,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":45},"100632251","phase-4-multicenter-trial-of-antithrombotic-strategies-in-acute-coronary-syndrome-with-coronary-artery-ectasia-100632251","NCT07511257","Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia","Dual Antiplatelet Therapy Versus Antiplatelet Monotherapy Plus Anticoagulation in Patients With Acute Coronary Syndrome and Coronary Artery Ectasia: A Multicenter Randomized Clinical Trial","OVER-TIME II","Inclusion Criteria:\n\n* Adults aged 18 to 80 years, of either sex, hospitalized with acute coronary syndrome (ACS) with or without ST-segment elevation.\n* Recent ACS within 7 days prior to enrollment, defined by all of the following:\n* Clinical presentation consistent with acute coronary syndrome.\n* Elevated high-sensitivity cardiac troponin above the 99th percentile.\n* Presence or absence of persistent ST-segment elevation.\n* Coronary artery ectasia in the culprit coronary artery, defined by all of the following:\n* The presence of ectasia will be determined by agreement of two expert interventional cardiologists, and will be confirmed by quantitative coronary angiography (QCA).\n* Identification of a culprit artery consistent with the electrocardiographic territory involved (in cases with ST-segment elevation) or with angiographic features suggestive of an atherothrombotic event, such as the presence of thrombus or reduced coronary flow.\n* Hospital admission lasting more than 24 hours.\n* Management with either percutaneous coronary intervention or medical therapy, as determined by the treating medical team. Intracoronary interventions such as stent implantation, balloon angioplasty, or thrombus aspiration are permitted.\n* Ability and willingness to provide written informed consent and to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Current indication for temporary or long-term anticoagulation therapy at the time of enrollment.\n* Severe chronic kidney disease, defined as KDIGO stage G4 or higher (estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² at hospital discharge.\n* History of major bleeding, active bleeding, or high bleeding risk, including but not limited to gastrointestinal bleeding, intracranial hemorrhage, or other conditions considered by the treating physician to confer a high risk of bleeding.\n* Advanced heart failure, defined as left ventricular ejection fraction (LVEF) \\\u003C30% plus at least one of the following:\n* More than two hospitalizations or unplanned emergency department visits for heart failure in the past year, or\n* NYHA functional class III or IV symptoms despite optimal medical therapy at enrollment or within the previous 3 months.",{"count":256,"type":23},326,[258],"PHASE4","Coronary artery ectasia (CAE) is a condition in which a coronary artery becomes abnormally dilated, measuring at least 50% larger than the adjacent normal segment. Although relatively uncommon, CAE is clinically important because it can lead to abnormal blood flow and increase the risk of blood clot formation. Patients with CAE are at higher risk of angina, myocardial infarction, and complications during coronary interventions. Despite these risks, the optimal antithrombotic treatment for patients with acute coronary syndrome (ACS) and CAE remains uncertain.\n\nDual antiplatelet therapy (aspirin plus clopidogrel) is currently the most commonly used treatment. However, the abnormal blood flow patterns observed in CAE may promote clot formation through mechanisms that could potentially be better addressed with anticoagulant therapy.\n\nThe OVER-TIME II trial is a multicenter randomized clinical trial designed to compare two antithrombotic strategies in patients with ACS and CAE: standard dual antiplatelet therapy versus antiplatelet monotherapy combined with anticoagulation. The study aims to determine whether the addition of anticoagulation reduces major cardiovascular events without significantly increasing bleeding risk.",[261,29,89,262],"Coronary Artery Ectasia","NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)",[261,264,265,266],"Acute Coronary Syndrome","Anticoagulation","Dual Antiplatelet Therapy","2026-04-06",{"date":269,"type":37},"2026-04-09",{"date":271,"type":37},"2026-02-11",{"date":273,"type":23},"2029-06",{"name":275,"class":74},"Instituto Nacional de Cardiologia Ignacio Chavez",{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":24,"phases":286,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":45},"100632020","phase-4-triple-vs-dual-lipid-lowering-therapy-for-ldl-c-reduction-in-acute-coronary-syndrome-100632020","NCT07508254","Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome","Triple (Atorvastatin, Ezetimibe, and Bempedoic Acid) Versus Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome: A Randomized Controlled Trial","TLD-ACS","Inclusion Criteria:\n\n1. Must be older than 18 years, male or female.\n2. Diagnosis of ACS (Acute Coronary Syndrome) is confirmed when hospitalized.\n3. Eligible for high-intensity statin therapy (atorvastatin)\n4. Patients can provide written informed consent.\n5. Patients will be eager to cooperate with study drugs and follow-up visits.\n\nExclusion Criteria:\n\n1. Intolerance or hypersensitivity to study drugs.\n2. Liver or ALT\u002FAST greater than three times the upper normal.\n3. Renal dysfunction: estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73 m².\n4. Gout with frequent bouts or severe hyperuricemia.\n5. Pregnancy\u002Flactation",{"count":285,"type":23},120,[258],"The goal of this clinical trial is to evaluate whether triple lipid-lowering therapy (atorvastatin, ezetimibe, and bempedoic acid) is more effective than dual therapy (atorvastatin and ezetimibe) in reducing LDL cholesterol levels in adults with acute coronary syndrome. It will also assess the safety of the treatment.\n\nThe main questions it aims to answer are:\n\n* Does triple therapy result in greater reduction in LDL-C compared to dual therapy?\n* What adverse effects occur in participants receiving triple therapy?\n\nResearchers will compare triple therapy to dual therapy to determine its effectiveness in lowering LDL-C levels.\n\nParticipants will:\n\n* Receive either dual or triple lipid-lowering therapy for 3 months\n* Attend regular follow-up visits for clinical assessment and laboratory testing\n* Undergo lipid profile evaluation at baseline and at the end of the study",[29,289],"Hypercholesterolemia",[291,292,293,294,295,264],"LDL-C Reduction","Statins","Ezetimibe","Bempedoic Acid","Randomized Controlled Trial","2026-04-03",{"date":269,"type":37},{"date":299,"type":23},"2026-05-01",{"date":301,"type":23},"2026-10-31",{"name":303,"class":74},"Punjab Institute of Cardology",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":312,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":24,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":45},"100632368","ivus-guided-vs-angiography-guided-pci-in-acute-coronary-syndrome-100632368","NCT07512778","IVUS-Guided vs Angiography-Guided PCI in Acute Coronary Syndrome","Clinical Impact of Intravascular Ultrasound-guided vs. Angiography-guided Coronary Stenting in Patients With Acute Coronary Syndrome: Multicenter, Randomized Control Trial (SAINT-IVUS)","SAINT-IVUS","Inclusion Criteria:\n\n1. Patients 19 years of age or older\n2. Patients with unstable angina pectoris, and acute MI including NSTEMI or STEMI.\n3. Coronary artery disease defined as \\>70% stenosis (reference vessel diameter 2.5 - 5.0 mm based on operator assessment) with identifiable culprit lesion indicated stent implantation\n4. All lesions must be suitable for treatment with the Synergy stent system, or other Synergy platform iteration\n5. The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Age \\>90 years\n2. Subject has known hypersensitivity or contraindication to device material and its degradants (everolimus, poly(L-lactide), poly(DL-lactide), lactide, lactic acid) and cobalt, chromium, nickel, platinum, tungsten, acrylic, and fluoro polymers that cannot be adequately premedicated.\n3. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to antiplatelet drugs, including both aspirin and P2Y12 inhibitors\n4. An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs within 6 m after the procedure.\n5. Cardiogenic shock\n6. Restenotic lesions\n7. Compromised left ventricular dysfunction (LVEF \\\u003C30%)\n8. At the time of screening, the subject has a malignancy that is not in remission\n9. Non-cardiac co-morbidities with a life expectancy less than 1 year\n10. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.\n11. Subject belongs to a vulnerable population (per investigator's judgment) or subject unable to read or write\n12. Concern for inability of the patient to comply with study procedures and\u002For follow-up (e.g., alcohol or drug abuse)\n13. Pregnancy","19 Years","90 Years",{"count":315,"type":23},1500,[85],"Coronary artery disease is associated with substantial morbidity and mortality worldwide. Percutaneous coronary intervention (PCI) is a pivotal procedure for the treatment of coronary artery disease. Although coronary angiography (CA) is the standard imaging modality used for coronary stent implantation, it provides only two-dimensional images of the coronary arteries. Intravascular ultrasound (IVUS) can provide additional information on plaque characteristics and vessel morphology, which may facilitate optimal stent sizing and procedural optimization. However, IVUS requires additional time and cost and may increase procedural complexity. Evidence regarding the clinical benefit of IVUS-guided PCI in patients with acute coronary syndrome (ACS) remains limited.\n\nThis study is a prospective, multicenter, randomized controlled trial designed to compare IVUS-guided PCI versus angiography-guided PCI in patients with ACS. A total of 1,500 participants will be randomized 1:1 to either the IVUS-guided group or the angiography-guided group. Participants will be recruited from 15 PCI centers in Korea. The primary outcome is target vessel failure at 2 years.",[29],[320,321,322],"Intravascular Ultrasound","IVUS-guided PCI","Angiography-guided PCI","2026-04-02",{"date":267,"type":37},{"date":326,"type":37},"2025-03-13",{"date":328,"type":23},"2031-12-31",{"name":330,"class":74},"SUK MIN SEO",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":339,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":24,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":45},"100629775","fexuprazan-for-prevention-of-upper-gastrointestinal-bleeding-in-high-bleeding-risk-patients-receiving-dual-antiplatelet-therapy-100629775","NCT07479056","Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy","Randomized Active-Controlled Trial Evaluating Fexuprazan for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention-Fexuprazan for Patients With Dual Antiplatelet Therapy Trial","SAINT-FEXUDAPT","Inclusion Criteria:\n\n* All four conditions below must be met.\n\n  1. Patients who are 20 years of age or older, have undergone coronary artery stent implantation for coronary artery disease, and require dual antiplatelet therapy for 6 months or longer.\n  2. Patients are considered to be at high bleeding risk if at least 1 criteria are met (Based on clinical recommendations (6,7,10,14-16) and expert consensus documents (17-19)) 1) Age ≥65 y 2) Low body weight (\\\u003C55 Kg for men, \\\u003C50 Kg for women) 3)Hemoglobin \\\u003C11g\u002FdL 4) Platelet count \\\u003C100×109\u002FL 5) Severe CKD: eGFR \\\u003C30mL\u002Fmin\u002F1.73m2,5 or on hemodialysis 6) Anticipated use of long-term oral anticoagulation (warfarin or direct-acting oral anticoagulants) 7) Long-term use of oral NSAIDs or steroids 8) Heart failure 9) A history of previous gastric or duodenal ulcer. 10) A history of previous gastrointestinal bleeding. 11)Previous or confirmed Helicobacter pylori infection\n  3. A voluntary participant in this clinical trial who has provided written consent, or a legal guardian who has provided written consent on behalf of the participant.\n  4. Those who agree to use a medically valid method of contraception\\* (including conditions in which pregnancy is medically impossible) during the clinical trial period Women who are medically unable to become pregnant can participate in this clinical trial: women who have undergone menopause (amenorrhea for more than 24 months), hysterectomy, salpingectomy, or bilateral oophorectomy, etc.\n* Medically valid contraceptive methods: intrauterine device (Loop, Mirena), physical barrier method (male condom, female condom (femidom)), subcutaneous contraception (Implanon, etc.), long-acting contraceptive injection, or tubectomy and ligation, vasectomy, etc. ( However, oral contraceptives cannot be used during this clinical trial, and it is recommended to use double contraception to prevent pregnancy while participating in this trial.)\n\nExclusion Criteria:\n\n1. Patients who have a hypersensitivity reaction to the components of this clinical trial drug or benzimidazole-based drugs or have a history of clinically significant hypersensitivity reaction\n2. Patients with contraindications to antiplatelet agents, such as allergies.\n3. Genetic blood coagulation disorders\n4. Cases in which the investigator determines that the use of dual antiplatelet therapy is difficult due to severe liver cirrhosis, thrombocytopenia, or other medical conditions.\n5. Hemodynamically unstable at the time of randomization (cardiogenic shock, uncontrolled arrhythmia, severe heart failure: NYHA Class IV).\n6. Patients with warning symptoms suspected of digestive malignancy (unintentional significant weight loss, recurrent vomiting, dysphagia, hematemesis, melena, etc.) within the past 3 months\n7. Patients with malignancy or serious illnesses with an expected survival of less than 1 year.\n8. Severe anemia (hemoglobin \\\u003C 8 g\u002FdL) or blood transfusion within 4 weeks of randomization.\n9. Active liver disease or impaired liver function (AST or ALT greater than three times the upper limit of normal).\n10. Advanced renal dysfunction: eGFR less than 30 mLmin\u002F1.73m2 or patients receiving dialysis\n11. Patients taking drugs contraindicated for this clinical trial drug (e.g., patients taking atazanavir, nelfinavir, or rilpivirine-containing preparations)\n12. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n13. Concurrently taking CYP 3A4 and p-glycoprotein (P-GP) inhibitors.\n14. Dementia or individuals unable to understand the trial procedures or comply with the trial requirements\n15. Pregnant or breastfeeding women, or women planning to become pregnant\n16. Individuals with active infections, significant hematologic, renal, metabolic, gastrointestinal, endocrine disorders, or any other reason the investigator deems the subject unsuitable for participation in the clinical trial","20 Years",{"count":341,"type":23},400,[85],"This study evaluates whether fexuprazan is effective in preventing upper gastrointestinal bleeding and related upper gastrointestinal clinical events in high bleeding risk patients who require dual antiplatelet therapy after coronary stent implantation.\n\nA total of 400 participants at a single center will be randomly assigned in a 1:1 ratio within 48 hours after stent implantation to receive either fexuprazan 40 milligrams or lansoprazole 30 milligrams once daily for 6 months. The study will compare upper gastrointestinal clinical events during follow-up",[29,345],"Coronary Artery Disease (CAD)",{"date":347,"type":37},"2026-04-08",{"date":349,"type":37},"2024-10-24",{"date":351,"type":23},"2028-12-31",{"name":330,"class":74},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":360,"targetDuration":4,"studyType":24,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":368,"leadSponsor":370,"locationsCount":45},"100632538","sirolimus-coated-vs-paclitaxel-coated-dcbs-in-acs-treatment-100632538","NCT07514988","Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment","Comparison Study of Sirolimus-Coated Versus Paclitaxel-Coated Coronary Drug-Coated Balloons in the Treatment of Acute Coronary Syndrome","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be enrolled:\n\n1. Age between 18 and 80 years old, both genders eligible;\n2. Coronary angiography showing non-complex lesions with acute coronary syndrome (non-ST-elevation myocardial infarction and unstable angina) deemed suitable for drug-coated balloon treatment by the investigator;\n3. Visually estimated lesion length ≤28mm, visually estimated vessel diameter ≥2.5mm and ≤3.0mm;\n4. Successful lesion pre-dilation (must simultaneously meet all 3 criteria: no Type C or greater dissection; TIMI flow grade 3; visually estimated residual stenosis ≤30%);\n5. Able to understand the study purpose, willing to complete follow-up visits, and voluntarily provide informed consent.\n\nExclusion Criteria:\n\nSubjects will be excluded if they meet any of the following criteria:\n\n1. Total occlusion (TIMI 0 flow) lesion;\n2. In-stent restenosis lesion;\n3. Concurrent left main disease or severe three-vessel disease requiring coronary artery bypass grafting;\n4. Target lesion with severe calcification or tortuosity that cannot be crossed by guidewire;\n5. Coronary artery bypass graft stenosis;\n6. Confirmed ST-elevation myocardial infarction;\n7. Cardiogenic shock or requiring mechanical respiratory and circulatory support;\n8. Hemodynamically unstable tachyarrhythmia or bradyarrhythmia;\n9. Severe renal insufficiency or undergoing hemodialysis;\n10. Known allergy or intolerance to aspirin, clopidogrel, ticagrelor, heparin, contrast media, paclitaxel, sirolimus and\u002For other analogues;\n11. Systemic lupus erythematosus or other systemic autoimmune diseases;\n12. History of stroke within 6 months prior to enrollment;\n13. Scheduled elective surgery within 6 months after enrollment requiring discontinuation of anticoagulant or antiplatelet medications;\n14. Currently participating in other drug or interventional medical device clinical studies;\n15. Other conditions deemed unsuitable for enrollment by the investigator.",{"count":113,"type":23},[85],"This study aims to investigate and compare the local inflammatory responses and plaque healing characteristics between sirolimus-coated and paclitaxel-coated coronary drug-coated balloons in patients with acute coronary syndrome.",[29],"2026-03-31",{"date":366,"type":37},"2026-04-07",{"date":299,"type":23},{"date":369,"type":23},"2028-07-01",{"name":371,"class":372},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":111,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":24,"phases":383,"briefSummary":384,"conditions":385,"keywords":388,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":411},"100629606","phase-4-effect-of-intravenous-iron-on-quality-of-life-in-older-patients-with-acute-coronary-syndrome-100629606","NCT07476859","Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome","Phase IV, Open-label, Randomized Clinical Trial on the Effect of Intravenous Iron on Quality of Life in Elderly Patients With Acute Coronary Syndrome","HI-COR-65","Inclusion Criteria:\n\n1. Age ≥ 65 years.\n2. Hospitalization for confirmed acute coronary syndrome (ACS) within 15 days prior to enrollment.\n3. Iron deficiency diagnosed at admission or within 15 days after the index ACS event, defined as:\n\n   * Serum ferritin \\\u003C 100 ng\u002FmL, OR\n   * Transferrin saturation (TSAT) \\\u003C 20%.\n4. Ability to provide written informed consent prior to participation.\n\nExclusion Criteria:\n\n1. Active malignancy.\n2. End-stage or terminal illness as determined by the IDC-Pal score.\n3. Known heart failure with left ventricular ejection fraction (LVEF) \\\u003C 40% prior to enrollment, or development of LVEF \\\u003C 40% during hospitalization or within 15 days after ACS.\n4. Chronic dialysis or advanced renal or hepatic failure.\n5. Severe anemia (hemoglobin \\\u003C 10 g\u002FdL) at the time of ACS or within 15 days after the event.\n6. Prior treatment with intravenous or oral iron within 12 months before the index ACS.\n7. Known hypersensitivity to ferric carboxymaltose, other parenteral iron products, or any component of the formulation.\n8. Evidence of iron overload or disorders of iron metabolism.\n9. Ongoing bacteremia or active systemic infection.\n10. Participation in another interventional clinical trial involving an investigational medicinal product.\n11. Any condition that, in the investigator's opinion, would compromise safety, protocol compliance, or study integrity.",{"count":382,"type":23},538,[258],"The goal of this phase IV, open-label, randomized clinical trial is to evaluate whether intravenous iron improves quality of life in adults aged 65 years and older with iron deficiency after an acute coronary syndrome (ACS).\n\nThe main questions it aims to answer are:\n\n* Does intravenous iron improve quality of life at 6 and 12 months?\n* Does it reduce frailty and adverse clinical outcomes?\n\nResearchers will compare intravenous ferric carboxymaltose with standard of care.\n\nParticipants will:\n\n* Be randomly assigned to receive intravenous iron or standard care\n* Attend three study visits over 12 months\n* Complete questionnaires and undergo blood tests",[29,386,387],"Iron Deficiencies","Elderly (People Aged 65 or More)",[124,389,390,391,392,393,394,395,396,397,398,399,400,401],"Iron deficiency","Intravenous iron","Ferric carboxymaltose","Quality of life","Older adults","Myocardial infarction","Frailty","Cardiovascular outcomes","Biological aging","ELOVL2 methylation","Telomere length","Klotho","FGF23","2026-03-20",{"date":404,"type":37},"2026-03-24",{"date":406,"type":37},"2026-03-05",{"date":408,"type":23},"2028-05",{"name":410,"class":74},"Fundación para la Investigación del Hospital Clínico de Valencia",9,{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":420,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":24,"phases":424,"briefSummary":425,"conditions":426,"keywords":427,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":45},"100625945","evaluation-through-innovative-examinations-of-intestinal-dysbiosis-status-in-patients-diagnosed-with-cardiovascular-diseases-and-evaluation-of-the-efficacy-of-natural-and-probiotic-extracts-in-the-non-pharmacological-approach-to-improving-intestinal-dysbiosis-status-100625945","NCT07429227","Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.","Metabolomic and Cellular Inflammaging Investigation Study of Patients With Acute Coronary Syndrome (ACS)","DISBIO","Inclusion Criteria:\n\n* 1\\. Signing of informed consent\n* 2\\. Diagnosis of Acute Coronary Syndrome (ACS)\n* 3\\. Age 30-70\n\nExclusion Criteria:\n\n1. Use in the three months preceding the signing of the informed consent of:\n\n   i) Lipid-lowering drugs containing statins, ezetimibe, fibrates ii) Lipid-lowering nutraceuticals containing monacolin K iii) Monoclonal antibodies that inhibit PCSK9 (proprotein convertase subtilisin\u002Fkexin type 9) such as Evolocumab and Alirocumab\n2. Diagnosis of conditions such as HIV, cancer and diabetes I and II Furthermore, if a female patient becomes pregnant during the trial, this will be one of the reasons for early exit from the study.","30 Years","70 Years",{"count":423,"type":23},15,[85],"The prospective experimental study aims to take an instantaneous photograph of the subject at time T0 and after 24 hours of intestinal permeability and dysbiosis indices in patients with acute coronary syndromes (ACS) which include unstable coronary artery disease (unstable angina) and acute myocardial infarction (AMI). The aim is to verify whether essential oils in particular formulations with high bioavailability are able to re-establish intestinal eubiosis after 2 months, confirmed by tests laboratory specifics such as metabolomics.",[29],[428,429,430,431,432,433,434],"intestinal permeability","unstable coronary artery disease","acute myocardial infarction","metabolomic","essential oils","dietary supplement","dysbiosis","2026-02-17",{"date":437,"type":37},"2026-02-24",{"date":439,"type":23},"2026-03",{"date":441,"type":23},"2027-03",{"name":443,"class":74},"Casa di Cura Dott. Pederzoli",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":24,"phases":453,"briefSummary":454,"conditions":455,"keywords":461,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":45},"100601244","drug-eluting-balloon-treatment-vs-guideline-directed-medical-therapy-for-the-treatment-of-lipid-rich-plaques-100601244","NCT07107971","Drug-Eluting Balloon Treatment vs. Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques","Drug-Eluting Balloon Treatment Versus Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques: A Randomized Controlled Trial","DELETE-LRP","Inclusion Criteria:\n\n* Presenting with acute coronary syndrome (ACS);\n* Successful PCI of a native coronary artery or major side branch;\n* At least 2 native coronary arteries are accessible for invasive coronary imaging; i.e. not totally occluded and \\>2 mm and \\\u003C6 mm reference vessel diameter.\n\nExclusion Criteria:\n\n* Hemodynamically unstable (presence of cardiogenic shock, need for intubation, need for inotropes);\n* Known hypersensitivity to paclitaxel;\n* Procedural complications of the index PCI;\n* Known renal insufficiency, i.e. eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2;\n* Hypersensitivity or allergy to contrast with inability to administer steroid and antihistamine premedication;\n* Presence of a comorbid condition with a life expectancy of less than one year;\n* Body weight \\>250 kg;\n* Subject belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or is unable to read or write.",{"count":341,"type":23},[85],"The goal of this clinical trial is to find out whether treating vulnerable plaques in the coronary arteries with a drug-coated balloon can make them less dangerous than using standard medication alone. The study includes adults with acute coronary syndrome (a type of heart problem caused by reduced blood flow in the coronary arteries).\n\nThe main questions the study aims to answer are:\n\n* Does the drug-coated balloon reduce the amount of fat inside the plaque more than medication alone?\n* Is this treatment safe for patients?\n\nParticipants will:\n\n* Undergo imaging of their coronary arteries during their planned heart procedure (PCI)\n* Be randomly assigned to receive either a drug-coated balloon treatment or no extra treatment\n* Undergo a heart scan (CT scan of the coronary arteries) within 2 weeks and again around 9 months after the procedure.\n* Undergo a second heart catherization 9 months later to examine changes in the plaque.",[60,456,457,458,459,460,29],"Atheroscleroses","Cardiovascular Disease","Vulnerable Coronary Plaques","Vulnerable Plaque","Lipid-Rich Atherosclerosis of Coronary Artery",[462,463,464,465,466,467,320,468,469],"Lipid-rich plaque","Vulnerable plaque","Near-infrared spectroscopy","Drug-coated balloon","Drug-eluting balloon","Paclitaxel-eluting balloon","Coronary computed tomography angiography","AI-QCT","2026-01-14",{"date":472,"type":37},"2026-01-15",{"date":474,"type":37},"2025-11-04",{"date":476,"type":23},"2033-01",{"name":478,"class":74},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":486,"targetDuration":4,"studyType":24,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":45},"100612874","influenza-vaccination-after-acute-coronary-syndrome-100612874","NCT07259252","Influenza Vaccination After Acute Coronary Syndrome","InVaACS","Inclusion Criteria:\n\n1. ACS patient aged from 18 to 80 years.\n2. Volunteer for the study and written informed consent.\n\nExclusion Criteria:\n\n1. Participate in any drug clinical trials within 3 months.\n2. Patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years.\n3. Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients).\n4. Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix).\n5. Patients refused to comply with the requirements of this study to complete the research work.\n6. Patients Received influenza vaccination within 1 year.\n7. Patients with contraindications for influenza vaccination.",{"count":487,"type":23},6620,[85],"The goal of this clinical trial is to learn if influenza vaccination can prevent adverse cardiac events in Chinese acute coronary syndrome patients. The main questions it aims to answer are:\n\n* Whether influenza vaccination can decrease events of cardiovascular death, MI, or stroke?\n* Whether influenza vaccination can decrease events of all cause death, unplanned revascularization, unplanned hospitalization for heart failure or for arrhythmia, stent thrombosis?\n\nIf there is a comparison group: Researchers will compare influenza vaccination and placebo to see if adverse cardiac events decrease.\n\nParticipants will receive an influenza vaccination or placebo after enrollment and phone calls for follow-up at 1 month, 3 months, 6 months and 1 year after discharge.",[29],"2026-01-10",{"date":493,"type":37},"2026-01-13",{"date":495,"type":37},"2025-12-03",{"date":497,"type":23},"2029-03-30",{"name":499,"class":74},"Tongji Hospital",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":24,"phases":510,"briefSummary":511,"conditions":512,"keywords":519,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":540},"100581693","one-hour-troponin-using-a-high-sensitivity-point-of-care-assay-in-emergency-primary-care-100581693","NCT06853626","One-hoUr Troponin Using a High-sensitivity Point-Of-Care Assay in Emergency Primary Care","Improved Management of Acute Chest Pain in Emergency Primary Care. The OUT-POC Study (One-hoUr Troponin Using a High-sensitivity Point-Of-Care Assay in Emergency Primary Care)","OUT-POC","Inclusion Criteria:\n\n* Patients (18+ years) with non-traumatic acute chest pain presenting in emergency primary care\n* Troponin testing requested by the treating physician\n\nExclusion Criteria:\n\n* Acute STEMI (direct hospital referral required)\n* Haemodynamically unstable (direct hospital referral required)\n* Not able to provide written, informed consent (i.e., due to time restraints, language barriers, impaired cognitive function, or other reasons)",{"count":509,"type":23},2500,[85],"Acute chest pain is a prevalent medical emergency in primary emergency care settings. Triage of chest pain prior to hospital admission presents significant challenges due to the absence of sufficiently sensitive diagnostic tools. Clinical signs, symptoms, risk assessment scores, or a normal electrocardiogram (ECG) can reliably exclude acute myocardial infarction (MI). This diagnostic uncertainty has resulted in chest pain being the second most common cause for acute hospital referrals from Norwegian emergency primary care, even though chest pain is frequently non-cardiac in origin.\n\nIn acute MI events, cardiac troponins are released into the bloodstream from the damaged myocardium, where low values are used to exclude MI. Until recently, such testing has necessitated using high-sensitivity cardiac troponin (hs-cTn) assays, which have been limited to hospital laboratories. However, recent technological advancements in point-of-care (POC) testing allow access to whole-blood assays that meet high-sensitivity criteria.\n\nIn this upcoming project, the investigators will evaluate the implementation of a whole-blood POC assay (QuidelOrtho TriageTrue hs-cTnI) across six Norwegian emergency primary care clinics. The study plans to enrol 2,500 patients over a period of 1.5 years. The clinical performance of the novel strategy will be investigated, as well as its impact on healthcare utilization and hospital referrals compared to standard care. Additionally, the investigators will assess the prevalence of persistent chest pain and its effects on quality of life, alongside psychological stress and anxiety, through validated questionnaires.\n\nThis project aims to offer better and more comprehensive management of the large group of emergency primary care patients with acute chest pain, contributing to reduced hospital referrals, improved quality of life, and more sustainable use of healthcare services.",[513,207,29,514,515,516,517,518],"Acute Myocardial Infarction (AMI)","Non-cardiac Chest Pain","Troponin","Point of Care Testing","Out-of-hours Medical Care","Primary Care",[520,521,522,523,524,525,526,527,528,430,529,506,530],"TriageTrue","POC","hs-cTnI","0\u002F1-hour algorithm","troponin","chest pain","primary care","OOH","out-of-hours","point-of-care","QuidelOrtho","2025-12-09",{"date":533,"type":37},"2025-12-10",{"date":535,"type":37},"2025-06-27",{"date":537,"type":23},"2029-12-31",{"name":539,"class":74},"University of Oslo",6,{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":548,"targetDuration":4,"studyType":24,"phases":550,"briefSummary":551,"conditions":552,"keywords":555,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":45},"100581840","phase-4-effectiveness-of-interventional-therapy-for-non-flow-limiting-vulnerable-plaques-100581840","NCT06855537","Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques","Randomized Controlled Study on the Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques","Inclusion Criteria Clinical Inclusion Criteria 1. Males or non-pregnant females aged 18-80 years 2. Clinically diagnosed with acute coronary syndrome (including unstable angina, ST-segment elevation myocardial infarction, and non-ST-segment elevation myocardial infarction) 3. Patients willing and able to sign a written informed consent form Angiography, QFR, and OCT Inclusion Criteria\n\n1. Successful completion of angiography, QFR, and OCT examinations\n2. Successful treatment of all culprit lesions and flow-limited lesions (QFR ≤ 0.8)\n3. Reference vessel diameter between 2.5-4.0 mm on imaging assessment\n4. Lesion length ≤40 mm\n5. At least one significant stenosis (diameter reduction \\>50%) demonstrated by angiography, with QFR \\>0.80 and OCT-defined TCFA (fibrous cap thickness \\\u003C65μm, lipid arc \\>90°)\n\nExclusion Criteria Clinical Exclusion Criteria\n\n1. Patients with contraindications to dual antiplatelet therapy (DAPT) or planning to discontinue DAPT within one year\n2. Patients with other major illnesses and a life expectancy \\\u003C2 years\n3. Patients scheduled for cardiac surgery or major non-cardiac surgery\n4. Women who are breastfeeding, pregnant, or planning pregnancy during the study\n5. Patients with severe heart failure (NYHA class III-IV or Killip class III-IV or left ventricular ejection fraction \\\u003C35%)\n6. Patients with estimated glomerular filtration rate \\\u003C30 mL\u002F(min·1.73 m²)\n7. Patients with allergy to contrast agents or DES drugs\n8. Patients currently enrolled in other clinical studies Angiographic Exclusion Criteria\n\n1\\. Patients for whom CABG is the preferred treatment 2. Target lesion is a previously stented lesion 3. Target lesion is a post-bypass lesion 4. Target lesion is a heavily calcified or angulated lesion 5. Target lesion requires dual-stent technique 6. Target lesion is a left main coronary artery lesion.",{"count":549,"type":23},2190,[258],"The aim of this clinical trial is to explore the optimal preventative treatment strategy for non-flow-limiting vulnerable plaques. The main question it aims to answer is:\n\nCan interventional therapy further improve the outcome of non-flow-limiting vulnerable plaques on top of optimal pharmacologic therapy?\n\nResearchers will randomly assign patients who meet the inclusion criteria to preventative intervention plus optimal drug therapy (experimental group) or optimal drug therapy alone (control group).\n\nParticipants will:\n\nAssigned to the control group: optimized drug therapy consisting of lifestyle improvement and intensive drug therapy including high-dose statin or other therapy to achieve target levels (low-density lipoprotein cholesterol \\\u003C1.4 mmol\u002FL and decreased by 50% compared to the baseline). Lifestyle improvement and risk factor management included smoking cessation, nutritional optimization, physical activity, compliance with prescribed medications, and control of diabetes and hypertension.\n\nAssigned to the experimental group: all non-flow-limiting vulnerable plaques were treated with conventional second-generation drug-eluting stents. After the procedure, participants received dual antiplatelet therapy for about 12 months as well as other medications in the control group.",[553,458,554,29],"Coronary Arterial Disease (CAD)","Thin-cap fIbroatheroma",[556,557,558,559,560,561,29,458],"Optical Coherence Tomography (OCT)","Percutaneous Coronary Intervention (PCI)","Randomized Controlled Trial (RCT)","Optimal Medical Therapy","Drug Eluting Stent (DES)","Quantitative Flow Ratio (QFR)","2025-11-25",{"date":564,"type":37},"2025-12-02",{"date":566,"type":37},"2025-11-03",{"date":568,"type":23},"2027-09-01",{"name":570,"class":74},"Beijing Anzhen Hospital",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":24,"phases":580,"briefSummary":581,"conditions":582,"keywords":584,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":599},"100606660","evaluation-of-the-effectiveness-of-an-interdisciplinary-intervention-after-acute-coronary-syndrome-on-low-density-lipoprotein-cholesterol-levels-100606660","NCT07178444","Evaluation of the Effectiveness of an Interdisciplinary Intervention After Acute Coronary Syndrome on Low-Density Lipoprotein Cholesterol Levels","EDUSCA","Inclusion Criteria:\n\n* Adult patients hospitalized for ACS (ST+ or ST-), affiliated with a social security scheme, able to understand the protocol and having signed the study consent.\n\nExclusion Criteria:\n\n* Patients with a complication of the ACS (mechanical complication, cardiogenic shock, very severe left ventricular dysfunction, presence of an intraventricular thrombus, complex ventricular rhythm disorder) ;\n* Proven cognitive impairment or decompensated psychological\u002Fpsychiatric disorder ;\n* Any progressive inflammatory and\u002For infectious condition ;\n* Any orthopedic problem precluding the physical activity ;\n* Current participation in any clinical research project aimed at reducing LDL cholesterol levels ;\n* Pregnant or breastfeeding woman ;\n* Patient receiving state medical assistance ;\n* Patient under guardianship or curatorship, or any other legal protection measure ;",{"count":579,"type":23},230,[85],"According to the World Health Organization (WHO), cardiovascular diseases are the worldwide leading cause of death. For the French public health, cardiovascular diseases are the leading cause of death for the women and the second for men. Each year in France, approximately 120,000 acute coronary syndromes (ACS) occur, including 60,000 myocardial infarctions and more than 15,000 deaths. To prevent or reverse this process, the WHO recommends early detection of the diseases and reduce behavioral and cardiovascular risk factors.\n\nFor the patient, the European Society of Cardiology (ESC) recommends the implementation of secondary prevention measures, the lifestyle modifications and the encouragement to become an actor in the management of his health. The first year, the medical follow-up is recommended at 3, 6 and 12 months.\n\nSince 2019, in order to reduce the impact of LDL cholesterol, the ESC has recommended that LDL cholesterol levels be lower than 0.55 g\u002FL accompanied by a reduction of at least 50% from their initial value. In 2023, it clarified this recommendation by recommending a laboratory reassessment within 4-6 weeks after hospital discharge.\n\nThe application of these recommendations comes up against the difficulties of real life:\n\n1. The increase in the number of elderly people and people with one or more chronic diseases;\n2. In France, the significant regional disparities in the number of physicians;\n3. In 2022, six months after hospitalization for an ACS, only 21.6% of French patients had benefited from a cardiac rehabilitation program;\n4. Within 12 months of acute coronary syndrome, only 20% to 40% of patients achieved the LDL cholesterol targets recommended by the ESC.\n\nGiven the difficulties in implementing the recommendations, investigators believe it is essential to rethink the care pathway for post-ACS patients.\n\nThe investigator's hypothesis is that, in addition to the standard pathway, a care offering access to other healthcare professionals (advanced practice nurse, dietitian, pharmacist) should increase the proportion of patients achieving LDL cholesterol targets (LDL cholesterol \\\u003C 0.55 g\u002FL and a 50% reduction in this level compared to the baseline value) at 12 months. LDL cholesterol was selected as the endpoint because it has been proven that a reduction in LDL cholesterol corresponds to a 22% reduction in cardiovascular events.\n\nTo test this hypothesis, the investigators designed a multicenter controlled and randomized trial with two parallel arms:\n\n* \"Routine Cares\" arm: Each center will program cares as usual and will schedule patient follow-up according to their wishes (cardiac rehabilitation, visits to the general practitioner and\u002For cardiologist).\n* \"Intervention\" arm: In addition to routine care as described above, the patient will receive an interdisciplinary consultation one month after hospital discharge and three consultations with the IPA (3, 6, and 12 months).\n\nIn order for the conclusions of this protocol to reflect French practices, it is planned to include 230 people who have presented with acute coronary syndrome in four healthcare facilities in France (both in Paris and outside Paris).",[29,583],"Acute Coronary Syndromes",[585,586,587,588,589],"acute coronary syndrome","dyslipidemias","patient education","multidisciplinary care team","nurse practitioners","2025-10-02",{"date":592,"type":37},"2025-10-03",{"date":594,"type":23},"2025-11",{"date":596,"type":23},"2028-11",{"name":598,"class":74},"Assistance Publique - Hôpitaux de Paris",4,{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":18,"minAge":420,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":24,"phases":608,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":45},"100607777","ecg-less-coronary-computed-tomography-angiography-in-the-management-of-patients-presenting-with-high-troponin-chest-pain-100607777","NCT07192965","ECG-less Coronary Computed Tomography Angiography in the Management of Patients Presenting With High-troponin Chest Pain","ECLECTIC","Inclusion Criteria:\n\n* Age ≥ 30 years old\n* Admission at the ER with acute chest pain and at least one of the follow-ing:\n\n  1. ECG abnormality;\n  2. positive rule-in criteria according to the ESC guidelines (hs-cTnT ≥ 52 in at least one assay or 1h ∆ ≥ 5);\n  3. troponine value in the \"observe pathway\" (hs-cTnT ≥ 12 in at least one assay or 1h ∆ ≥ 3) AND a high clinical suspicion of MI.\n\nExclusion Criteria:\n\n* Indication for urgent ICA (ST-elevation, hemodynamic or electric instabil-ity, refractory chest pain, mechanical complications)\n* eGFR \\\u003C 30 ml\u002Fmin\n* Previous coronary stenting\n* Previous CABG\n* Recent ACS within 6 months\n* Known severely reduced ejection fraction (EF \\\u003C 30%)\n* Contrast allergy\n* Inability to provide informed consent\n* Limited life expectancy \\\u003C 2 years due to non-cardiac conditions\n* Pregnant and breast-feeding women\n* Known congenital heart disease\n* Atrial fibrillation",{"count":579,"type":23},[85],"Chest pain represents a common reason for consultation to emergency room. This symptom can be explained by a broad spectrum of conditions, from benign musculoskeletal or esophageal pain to life-threatening disease such as aortic dissection, pulmonary embolism, and myocardial infarction.\n\nThere are already different diagnostic tools to quickly identify most dangerous diseases, for example electrocardiogram, blood samples with specific markers of cardiac injury, chest X-ray and echography. In case a doubt of disease is raised after the first clinical evaluation, it is possible to proceed with more complex, expensive and invasive examinations, namely a computed tomography (CT) scan or an invasive coronary angiography (ICA).\n\nCT scan allows the diagnosis of various conditions such as pleural, pulmonary, pericardial and vascular disease such as pneumonia, pneumothorax, pleural and pericardial fluid, pulmonary embolism (PE), acute aortic dissection (AOD). In order to see the pulmonary, aortic and coronary arteries, a contrast injection is needed. Moreover, since the heart and the aortic root are continuously moving, specific technical measures to obtain good quality images are needed.\n\nRecently, a new CT scan system has been developed. It allows to obtain good quality images of the heart and aortic root using an estimated heart rhythm, without ECG-gating. This allows to perform a CT scan of the heart in a reduced amount of time, and without need for controlling heart rate. Moreover, it is possible to obtain information on both aortic, coronary, and pulmonary artery with the same contrast injection. This may be of great interest in the context of patients presenting at the emergency room with chest pain and with a suspicion of pulmonary embolism, myocardial infarction, or aortic dissection, since with a single fast exam it is possible to rule out all these conditions.\n\nCoronary arteries are very small vessels, and the accuracy of this new technique in identifying a significant obstruction is still to be proved. At present, patients with chest pain and a suspicion of myocardial infarction undergo an invasive coronary angiography. If this new tool proves to be reliable, it will be possible to reduce the number of useless invasive examination in patients in which the presence of coronary artery disease (CAD) is ruled-out. In addition, the CT scan can help quickly and effectively plan treatment when worrying abnormalities are detected in the coronary arteries that are associated with a higher risk.\n\nTherefore, this clinical trial (further on referred to as \"trial\") will evaluate the investigational medicinal product (IMP), ECG-less Revolution Apex Elite system (GE Healthcare, Waukesha, WI -USA) for the diagnosis of coronary artery disease. The purpose of this trial is to learn about: the accuracy of this new CT system compared to the gold standard invasive coronary angiography in diagnosing coronary artery disease. The number of patients receiving an alternative diagnosis such as pulmonary embolism, aortic dissection, pulmonary, pleural or pericardial disease will be evaluated. Finally, the prognostic predictive value of the CT compared with ICA, in predicting myocardial infarction, coronary revascularization, and cardiac death at a follow-up of 18 months will be assessed. Patient will undergo a computer tomography examination with this new technique, evaluating both pulmonary, aortic, and coronary arteries. Then, as indicated by current guidelines, they will undergo an invasive coronary angiography.",[207,29],[612,124,613,614,615],"Chest pain","NSTEMI","ECG-less coronary computed tomography angiography","ECG-les CCTA","2025-09-23",{"date":618,"type":37},"2025-09-25",{"date":620,"type":37},"2025-09-10",{"date":622,"type":23},"2028-03",{"name":624,"class":74},"Universitair Ziekenhuis Brussel",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":633,"conditions":634,"keywords":637,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":653},"100601596","occurrence-of-severe-cardiac-rhythm-and-conduction-disturbances-in-emergency-department-patients-with-non-st-elevation-acute-coronary-syndrome-100601596","NCT07112547","Occurrence of Severe Cardiac Rhythm and Conduction Disturbances in Emergency Department Patients With Non-ST Elevation Acute Coronary Syndrome","SurvSCA","Inclusion Criteria:\n\n* Adult (≥ 18 years old) patient admitted to the emergency department\n* Able to understand the information provided\n* Diagnosis of non-ST segment elevation ACS established according to the lastest guidelines from the European Society of Cardiology and the 4th Universal Definition of myocardial infarction\n* No objection to participation in the study after receiving appropriate information\n\nExclusion Criteria:\n\n* Patients subject to legal protection\n* Patient with cognitive impairment\n* Myocardial injury and\u002For symptoms attributable to Takotsubo syndrome, myocarditis, pericarditis, or acute heart failure\n* Clinical evidence suggestive of type 2 myocardial infarction, including acute anemia with hemoglobin \\\u003C 10 g\u002FdL, sepsis, acute hypoxemic respiratory failure",{"count":197,"type":23},"Cardiovascular diseases are the leading cause of death worldwide. Among them, coronary artery disease-especially in its acute form, known as acute coronary syndrome (ACS)-is the most frequent cause of cardiovascular death. There are two main types of ACS: ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS). While the occurrence of serious heart rhythm and conduction disturbances is well established in STEMI, these complications are believed to be much less frequent in NSTE-ACS. However, their actual frequency in this population remains unclear due to limited studies, especially in emergency settings.\n\nThe main purpose of this study is to estimate the frequency of serious rhythm and conduction disorders in patients presenting with NSTE-ACS in emergency departments. The hypothesis is that these events are rare in this population and may not justify routine continuous cardiac monitoring for all such patients, as currently recommended.\n\nSecondary objectives include identifying risk factors for these complications, estimating their frequency during hospitalization, assessing the frequency of minor rhythm and conduction disorders, evaluating care times and patient flow in emergency departments, and assessing patient outcomes up to 30 days-including hospitalizations, length of stay, discharge disposition, all-cause mortality, and the occurrence of five major adverse cardiovascular events (5-point MACE).",[635,29,636],"Acute Coronary Syndrome Without ST Elevation on Electrocardiogram","Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease",[638,639,640,641,642,643],"Non-ST Segment Elevation Acute Coronary Syndrome","Cardiac Arrhythmias","Heart Conduction System Disease","Hospital Emergency Service","Electrocardiographic monitoring","Cardiovascular diseases","2025-08-01",{"date":646,"type":37},"2025-08-08",{"date":648,"type":23},"2025-09-01",{"date":650,"type":23},"2028-10-01",{"name":652,"class":74},"University Hospital, Strasbourg, France",10,{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":660,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":662,"targetDuration":4,"studyType":24,"phases":664,"briefSummary":665,"conditions":666,"keywords":670,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":677,"lastUpdatePostDateStruct":678,"startDateStruct":680,"completionDateStruct":682,"leadSponsor":684,"locationsCount":45},"100595885","patient-centered-personalized-cardiac-rehabilitation-in-post-acute-coronary-syndrome-break-trial-100595885","NCT07038265","Patient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial)","Patient-centered Cardiac rehaBilitation pRogramE in Post Acute Coronary Syndrome:Identification of Key Barriers and Evaluation of Personalized Intervention (BREAK-trial)","BREAK","Inclusion Criteria:\n\n1. Patient aged ≥ 18 years\n2. Patients discharged within the last 30 days after an admission for ACS or in the discharge planning process for an admission for ACS.\n3. The patient is able to fully communicate with the research team and comply with all study procedures.\n4. The patient voluntarily signs and dates the informed consent form approved by the ethics committee\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Participation in another clinical trial\n3. Moderate or severe cognitive impairment in the absence of a competent caregiver\n4. Absence of social support\n5. Institutionalized patient\n6. Life expectancy \\\u003C1 year\n7. Candidates for end-of-life care\n8. Severe psychiatric illness\n9. Planned cardiac surgery including transplant or circulatory support implant\n10. Death before hospital discharge in patients included in the hospital discharge planning phase\n11. Carrier of heart transplant.\n12. Patient unable or refusing to give written informed consent to participate\n13. Patients who, in the opinion of the investigator, are unsuitable candidates for the study",{"count":663,"type":23},202,[85],"The primary objective of this study is to compare an integrated, multidisciplinar patient-centered CRP (Cardiac Rehabilitation Program) (intervention group) especially focused on covering the needs for the female and fragile population to the usual care conventional CRP (control group)",[29,667,395,668,669],"Cardiac Rehabilitation","Women","Women's Health",[671,672,673,674,585,675,676],"frailty","sarcopenia","cardiac rehabilitation","gender perspective","coronary artery disease","patient-centered care","2025-06-17",{"date":679,"type":37},"2025-06-26",{"date":681,"type":37},"2025-05-26",{"date":683,"type":23},"2027-11",{"name":685,"class":74},"Institut d'Investigació Biomèdica de Bellvitge",{"id":687,"slug":688,"hasResults":12,"nctId":689,"briefTitle":690,"officialTitle":691,"acronym":4,"eligibilityCriteria":692,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":693,"targetDuration":4,"studyType":24,"phases":695,"briefSummary":696,"conditions":697,"keywords":699,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":710,"lastUpdatePostDateStruct":711,"startDateStruct":713,"completionDateStruct":715,"leadSponsor":716,"locationsCount":45},"100587476","ticin-pilot-study-sirolimus-eluting-balloon-for-stabilization-and-regression-of-non-obstructive-coronary-plaques-100587476","NCT06928883","Ticin Pilot Study: Sirolimus-Eluting Balloon for Stabilization and Regression of Non-Obstructive Coronary Plaques.","TITAN-PARADISE Pilot: TicIn for the Treatment of Coronary Lesions - Plaque Regression and Stabilization With Sirolimus Elution (Pilot Study)","Inclusion Criteria:\n\nPotential subjects must fulfill all following inclusion criteria:\n\n1. Multivessel coronary artery disease with ACS within 90 days prior to inclusion and successful interventional treatment of the culprit lesion\n2. Presence of ≥ 2 de novo non-culprit lesion without hemodynamic relevance in two different coronary vessels (demonstrated either by wire-based or angiography-based coronary physiology) and with MaxLCBI4mm ≥ 325 at baseline IVUS-NIRS\n3. Age ≥ 18 years\n4. Written informed consent\n\nExclusion Criteria:\n\nPatients are not eligible if any of the following applies:\n\n1. Non culprit lesion involving the left main and\u002For ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery;\n2. Non-culprit lesion in a previously stented segment (i.e. within 15 mm from the previously implanted stent);\n3. Non-culprit lesion involving small vessel (\\\u003C3.0 mm) deemed not suitable to PCI,\n4. Non-culprit lesion located in a bypass graft or in a grafted vessel;\n5. Severe renal impairment (eGFR\\\u003C15ml\u002Fmin\u002F1.73m2) or patient on dialysis treatment;\n6. Known pregnancy r breast-feeding patients;\n7. Life expectancy \\\u003C2 year due to other severe non-cardiac disease;\n8. Legally incompetent to provide informed consent;\n9. Partecipation in another clinical study with an investigational product",{"count":694,"type":23},24,[85],"The goal of this pilot clinical trial is to evaluate the use of the Selution SLR sirolimus-eluting balloon, in addition to guideline-directed medical therapy (GDMT), for the preventive treatment of non-flow-limiting vulnerable coronary lesions, compared to GDMT alone, in adult patients with multivessel coronary artery disease and a recent acute coronary syndrome (within 90 days).\n\nThe main research question is:\n\nDoes the use of the Selution SLR sirolimus-eluting balloon in combination with GDMT reduce the progression and vulnerability of non-flow-limiting vulnerable coronary plaques?\n\nParticipants will undergo\n\n* PCI procedure with baseline IVUS-NIRS assessment\n* Follow-up coronary angiography at 6 months with IVUS-NIRS assessment\n* Clinical follow-up at 3, 6, and 24 months after study enrollment",[553,458,90,698,29],"Coronary Vessel",[553,458,700,701,29,702,703,704,705,706,707,708,709],"Multivessel coronary artery disease","Coronary vessel","Non-flow limiting vulnerable coronary plaques","Sirolimus-eluting DEB","DEB Selution SLR","Guidelines-directed medical therapies (GDMT)","IVUS-NIRS","MaxLCBI4mm","MaxLCBI4mm≥325","Lipid Core Burden Index (LCBI)","2025-04-08",{"date":712,"type":37},"2025-04-15",{"date":714,"type":23},"2025-04",{"date":351,"type":23},{"name":717,"class":74},"Cardiocentro Ticino",{"id":719,"slug":720,"hasResults":12,"nctId":721,"briefTitle":722,"officialTitle":723,"acronym":724,"eligibilityCriteria":725,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":726,"targetDuration":4,"studyType":24,"phases":727,"briefSummary":728,"conditions":729,"keywords":731,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":737,"lastUpdatePostDateStruct":738,"startDateStruct":739,"completionDateStruct":741,"leadSponsor":742,"locationsCount":45},"100582305","effect-of-point-of-care-analysis-of-ultrasensitive-troponin-i-on-length-of-hospital-stay-in-patients-with-cardiac-chest-pain-poc-troponina-100582305","NCT06861582","Effect of Point-of-care Analysis of Ultrasensitive Troponin I on Length of Hospital Stay in Patients With Cardiac Chest Pain (POC Troponina)","Effect of Point-of-care Analysis of Ultrasensitive Troponin I on Length of Hospital Stay in Patients With Cardiac Chest Pain: a Randomized Study (POC Troponina)","POC Troponina","Inclusion Criteria:\n\n* Patients aged ≥ 18 years.\n* Patients arriving in the emergency room with symptoms suggestive of ACS, with onset of pain between 3 and 12 hours after arrival, in whom serial troponin dosing is planned for investigation.\n* Signature of the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Patients presenting with ACS with ST-segment elevation on the 12-lead ECG on arrival at hospital.\n* Patients with conditions that interfere with the interpretation of troponin dosage (chronic renal failure, cancer, chronic lung diseases).\n* Pregnant or breastfeeding patients.\n* Patients already included in other clinical research protocols.",{"count":144,"type":23},[85],"This clinical study aims to compare two different methods for measuring high-sensitivity troponin I, a key biomarker used to diagnose heart attacks.\n\nThe primary research question is: Does the use of the Atellica VTLi kit from Siemens for high-sensitivity troponin I (hs-cTnI) testing at the point of care (POC) significantly reduce the average time from admission to hospital discharge compared to the conventional laboratory methodology using the Alinity i kit from ABBOTT?\n\nParticipant will:\n\n* Patients aged ≥ 18 years.\n* Patients arriving in the emergency room with symptoms suggestive of ACS, with onset of pain between 3 and 12 hours after arrival, in whom serial troponin dosing is planned for investigation.\n* Signature of the Informed Consent Form (ICF).\n\nResearchers will analyze whether the point-of-care testing method helps speed up the hospital discharge process compared to the standard laboratory approach. They will also compare the accuracy of the test results, the time taken for clinical decisions, and the overall cost-effectiveness of the two methods.",[29,730,204],"Troponin I",[264,732,730,204,733,734,149,735,736],"Non-ST Elevation Myocardial Infarction","Biomarkers","Emergency Service, Hospital","Cardiovascular Diseases","Hospital Length of Stay","2025-04-07",{"date":710,"type":37},{"date":740,"type":37},"2025-03-10",{"date":439,"type":23},{"name":743,"class":74},"University of Sao Paulo"]